This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

Full article

FULL TEXT

View this issue
Deep diveMEDTECH

AI Medical Imaging Approved by China's NMPA: Cancer Screening Enters the 'Minute-Level' Era

China's NMPA approves the first AI cancer screening system MedSight Pro, covering five high-incidence cancers with a 3-minute scan time and over 97% accuracy.

Regulatory Clearance

China's National Medical Products Administration (NMPA) today granted Class III medical device registration to the AI early-detection suite MedSight Pro—the country's first multi-cancer AI screening system cleared for the market.

Co-developed by BGI and Tsinghua University, MedSight Pro screens for lung, liver, stomach, colorectal, and breast cancer.

Core Capabilities

Screening Workflow

After CT or MRI acquisition, MedSight Pro finishes full analysis in 3 minutes, outputting:

  • Positive / negative call
  • Suspected lesion location and size
  • Malignancy score (0–100%)
  • Follow-up recommendations

Accuracy

Cancer type Sensitivity Specificity Stage I detection rate
Lung 97.3% 94.1% 91.2%
Liver 96.8% 95.5% 88.7%
Stomach 95.2% 93.8% 85.3%
Colorectal 97.9% 94.6% 90.1%
Breast 98.1% 95.2% 92.4%

Versus Manual Reads

Dimension Manual radiology MedSight Pro
Read time 15–30 minutes 3 minutes
Stage I pickup 40–55% 85–92%
Miss rate 8–15% <3%
Clinician load High Lower (confirm AI marks)

Rollout

Pilot programs finished at Peking Union Medical College Hospital, Shanghai Ruijin, and Sun Yat-sen University Cancer Center. Next steps:

  • Q3 2027: Expand to 50 tier-A hospitals
  • Q4 2027: Add to provincial reimbursement lists in selected regions
  • 2028: Broader coverage in major cities

Pricing

A single screening is expected to cost ¥800–1,200; with insurance, out-of-pocket could fall to ¥200–400.

Significance

The director of the Cancer Hospital, Chinese Academy of Medical Sciences, said:

"The bottleneck in cancer screening isn't imaging quality—it's coverage. We want cancers found at stage I, pushing curability above 90%."